← All trials
NCT03955380
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 12, 2018
- Primary completion
- Apr 3, 2019
- Completion date
- Apr 3, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ViennaLead sponsor
- Medical University of ViennaCollaborator
- Alzheimer's AssociationCollaborator
- University of ViennaOverall official - principal investigator
- Nuvisan Pharma ServicesCollaborator
- NeuroScios GmbHCollaborator
- Helmholtz Centre for Infection ResearchCollaborator
- Fundación Teófilo Hernando, SpainCollaborator
- Forschungszentrum JülichSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.